- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The EMA Turns 20: What Does It Want to Be?
The European Medicines Agency (EMA) is 20 years old this year - and it confronts many of the problems familiar to anyone at that age.
The European Medicines Agency (EMA) is 20 years old this year - and it confronts many of the problems familiar to anyone at that age. After the vigorous growth and boundless optimism of its early adolescence, the agency now must make up its mind about what it wants to be.
This is not just a matter of defining its personality. It also means taking on greater responsibility obtaining the resources it will need, and asserting its mission successfully in the face of the often harsh realities of the outside world.
The agency’s own sharpened awareness of the complex conditions beyond Canary Wharf, London, offices is its programme for 2014, which identifies half a dozen new priorities. As EMA’s executive director, Guido Rasi, publicly observed at the end of last year, “The environment in which we are operating is ever-changing, continuously presenting us with new challenges.”
For Reflector’s incisive look at the EMA’s growing pains as it faces the key policy challenges of 2014, see February’s issue of Pharmaceutical Executive, or click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
